Guardant Health Slides as Investors Appear to Take Profits After Recent Rally

Guardant Health (GH) is down 6.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a pullback after a sharp run-up in the shares over the past week, rather than a clearly negative new company announcement. Recent news flow has actually been favorable, so today’s decline could be because traders are locking in gains while the stock sits near recent highs ahead of late-July earnings.

Details:

Guardant Health said on July 1 that UnitedHealth Group now covers its Shield blood test for colorectal cancer screening, expanding access through a major commercial insurer and lifting enthusiasm around the company’s screening business.

Several analysts raised their price targets in the days that followed, including moves to $190, $200, and even $215, showing that Wall Street sentiment remained constructive after the coverage expansion.

The company is expected to report second-quarter results on July 30, 2026, which may be encouraging some investors to reduce risk after the recent surge and wait for fresh operating data.

Recent SEC-related filings also showed routine equity vesting, tax-withholding share dispositions, and a small proposed resale filing, which may have added a modest source of supply even if they do not point to a fundamental problem.

Sources:

Business Wire, SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GH Insider Trading Activity

$GH insiders have traded $GH stock on the open market 65 times in the past 6 months. Of those trades, 1 have been purchases and 64 have been sales.

Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 19 sales selling 520,000 shares for an estimated $67,405,344.
HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 7 sales selling 100,000 shares for an estimated $12,629,968.
KUMUD KALIA (Chief Information Officer) has made 1 purchase buying 600 shares for an estimated $78,456 and 6 sales selling 49,618 shares for an estimated $5,067,010.
JOHN G. SAIA (Chief Legal Officer) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $3,381,064.
CHRIS FREEMAN (Chief Commercial Officer) sold 24,406 shares for an estimated $2,896,360
TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 7 sales selling 22,434 shares for an estimated $2,457,331.
MEGHAN V. JOYCE has made 0 purchases and 4 sales selling 10,000 shares for an estimated $1,269,808.
STEVE E. KROGNES sold 9,294 shares for an estimated $1,231,521
IAN T CLARK sold 6,876 shares for an estimated $735,048
MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $518,351.
MEDINA MANUEL HIDALGO has made 0 purchases and 5 sales selling 3,550 shares for an estimated $382,920.
MUSA TARIQ has made 0 purchases and 5 sales selling 2,647 shares for an estimated $322,622.
MYRTLE S POTTER sold 1,556 shares for an estimated $204,084

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive GH Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GH Hedge Fund Activity

We have seen 229 institutional investors add shares of $GH stock to their portfolio, and 203 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TWO SIGMA INVESTMENTS, LP added 2,057,628 shares (+94.7%) to their portfolio in Q1 2026, for an estimated $190,063,098
PIER 88 INVESTMENT PARTNERS LLC added 2,050,380 shares (+30064.2%) to their portfolio in Q1 2026, for an estimated $189,393,600
GOLDMAN SACHS GROUP INC added 1,808,266 shares (+68.8%) to their portfolio in Q1 2026, for an estimated $167,029,530
FMR LLC added 1,719,648 shares (+71.8%) to their portfolio in Q1 2026, for an estimated $158,843,885
PRICE T ROWE ASSOCIATES INC /MD/ added 1,387,611 shares (+24.6%) to their portfolio in Q1 2026, for an estimated $128,173,628
JENNISON ASSOCIATES LLC removed 966,559 shares (-82.6%) from their portfolio in Q1 2026, for an estimated $89,281,054
WESTFIELD CAPITAL MANAGEMENT CO LP added 823,349 shares (+152.7%) to their portfolio in Q1 2026, for an estimated $76,052,747

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GH Analyst Ratings

Wall Street analysts have issued reports on $GH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/20/2026

To track analyst ratings and price targets for $GH, check out Quiver Quantitative's $GH forecast page.

$GH Price Targets

Multiple analysts have issued price targets for $GH recently. We have seen 20 analysts offer price targets for $GH in the last 6 months, with a median target of $155.0.

Here are some recent targets:

Patrick Donnelly from Citigroup set a target price of $215.0 on 07/08/2026
Michael Ryskin from B of A Securities set a target price of $190.0 on 07/06/2026
Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
Eve Burstein from Bernstein set a target price of $200.0 on 07/02/2026
Mark Massaro from BTIG set a target price of $190.0 on 07/01/2026
Subbu Nambi from Guggenheim set a target price of $160.0 on 06/29/2026
Luke Sergott from Barclays set a target price of $150.0 on 06/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.